| CMT | California mastitis test; cancer multistep therapy; catechol methyltransferase; certified medical tr... |
|---|---|
| DMA | department of medical assistance; dimethylamine; dimethylaniline; dimethylarginine; direct memory ac... |
| DRAM | dynamic random access memory |
| EM | early memory; ejection murmur; electromagnetic; electron micrograph; electron microscopy, electron m... |
| EPROM | erasable programmable read-only memory |
| subconscious memory | Information not immediately available for recall. (05 Mar 2000) |
|---|---|
| immunological memory | <immunology> The systems responsible for the situation where reactions to a second or subsequent exposure to an antigen are more extensive than those seen on first exposure (but See immunological tolerance. The memory is best explained by clonal expansion and persistence of such clones following the first exposure to antigen. (18 Nov 1997) |
| temporary memory | <psychology> Temporary storage of information for a few seconds to hours, as opposed to long-term memory which refers to material stored for days, years, or a lifetime. (12 Dec 1998) |
| long-term memory | That phase of the memory process considered the permanent storehouse of information which has been registered, encoded, passed into the short-term memory, coded, rehearsed, and finally transferred and stored for future retrieval; material and information retained in LTM underlies cognitive abilities. (05 Mar 2000) |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |